©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 14, 2015; 21(18): 5445-5453
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445
MET inhibitors for treatment of advanced hepatocellular carcinoma: A review
Xing-Shun Qi, Xiao-Zhong Guo, Hong-Yu Li, Jiang Chen, Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 100840, Liaoning Province, China
Xing-Shun Qi, Guo-Hong Han, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Author contributions: Qi XS conceived this work, performed the literature search and selection, and drafted the manuscript; Guo XZ, Han GH, Li HY and Chen J gave critical comments and revised the manuscript; all authors have made an intellectual contribution to the manuscript and approved the submission.
Conflict-of-interest: All authors disclosed no conflicts of interest for this work.
Correspondence to: Xiao-Zhong Guo, MD, PhD, Professor, Department of Gastroenterology, General Hospital of Shenyang Military Area, No. 83 Wenhua Road, Shenyang 110840, Liaoning Province, China. guo_xiao_zhong@126.com
Telephone: +86-24-28897603 Fax: +86-24-28851113
Received: December 10, 2014
Peer-review started: December 10, 2014
First decision: December 26, 2014
Revised: January 9, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: May 14, 2015
Processing time: 158 Days and 23 Hours
Peer-review started: December 10, 2014
First decision: December 26, 2014
Revised: January 9, 2015
Accepted: February 11, 2015
Article in press: February 11, 2015
Published online: May 14, 2015
Processing time: 158 Days and 23 Hours
Core Tip
Core tip: MET inhibitors are being tested as the first-line or second-line therapy for advanced hepatocellular carcinoma after the failure of a loco-regional or systemic therapy, especially in patients with high MET expression. Ongoing phase III randomized controlled trials will provide the decisive recommendations regarding the use of MET inhibitors in advanced hepatocellular carcinoma.